Cholesterol-Lowering Medications —
Compared

Atorvastatin is the most prescribed statin in the world and one of the most prescribed medications of any kind. Its combination of high LDL-lowering potency, once-daily dosing flexibility (it can be taken at any time of day due to its long half-life), and extensive safety data across decades makes it a reliable first-line choice for most patients who need a statin.

Available in 10mg, 20mg, 40mg, and 80mg tablets, atorvastatin spans a wide potency range within a single drug — from moderate LDL lowering at 10mg to over 50% reduction at 80mg. This flexibility means prescribers can step up the same medication rather than switching agents when intensification is needed.

Atorvastatin is metabolized by CYP3A4. This is the most important practical consideration: drugs that inhibit CYP3A4 — including certain antibiotics, antifungals, and HIV medications — can significantly raise atorvastatin blood levels and increase the risk of muscle-related side effects. Always disclose all medications to your prescriber and pharmacist.

Rosuvastatin is the most potent statin on a per-milligram basis and produces among the largest LDL reductions of any statin available. Available in 5mg, 10mg, 20mg, and 40mg tablets, it achieves LDL reductions of 45–55% at moderate-to-high strengths.

Its key pharmacological differentiator from atorvastatin is its metabolic pathway: rosuvastatin is primarily metabolized by CYP2C9, not CYP3A4. This means the large category of CYP3A4 inhibitors — antibiotics like clarithromycin, antifungals like fluconazole, many HIV medications — are far less likely to raise rosuvastatin levels. For patients on complex medication regimens, this can be a decisive advantage.

At very high strengths (40mg), rosuvastatin can cause mild proteinuria (protein in the urine). This is usually benign and resolves with strength reduction, but it warrants monitoring. Rosuvastatin is generally preferred over atorvastatin when the lowest possible dose is needed or when CYP3A4 interactions are a concern.

Simvastatin was one of the original widely used statins and generated landmark clinical trial data (4S, HPS) that established statins' cardiovascular mortality benefit. It remains widely prescribed, primarily because of its availability as an inexpensive generic in multiple strengths.

Available in 5mg, 10mg, 20mg, 40mg, and 80mg tablets. However, the 80mg strength carries an important FDA restriction: it should not be initiated in new patients because the myopathy risk at this strength is substantially higher than at 40mg. The 80mg is only continued in patients who have already been on it long-term without muscle problems.

Simvastatin is metabolized by CYP3A4, and because it is already a widely used generic with known interaction risks, many patients on simvastatin are recommended to switch to rosuvastatin or pravastatin when a new CYP3A4-affecting medication is added. Evening dosing is preferred since cholesterol synthesis is highest overnight.

Pravastatin occupies a unique niche among statins: it is not meaningfully metabolized by cytochrome P450 enzymes at all. Instead, it is eliminated through a combination of hepatic uptake, sulfation, and renal excretion. This pharmacokinetic profile gives it the lowest drug interaction burden in the statin class by a significant margin.

This makes pravastatin the preferred statin in settings where drug interactions are a dominant concern — most notably in solid organ transplant recipients, who typically take cyclosporine or tacrolimus (both CYP3A4-inhibiting immunosuppressants that would raise levels of other statins dramatically). Pravastatin levels are relatively unaffected.

The trade-off is lower LDL-lowering potency: pravastatin produces 20–35% LDL reductions across its available strengths (10mg, 20mg, 40mg, 80mg). For patients who need only moderate LDL reduction and have complex medication regimens, it is an excellent choice. Available as an inexpensive generic.

Pitavastatin is a newer statin with a distinctive profile: like pravastatin, it has minimal dependence on CYP enzyme metabolism (primarily glucuronidated by UGT enzymes), giving it a favorable drug interaction profile. Unlike pravastatin, pitavastatin achieves higher potency — comparable to moderate-intensity atorvastatin or rosuvastatin use — at relatively small milligram amounts (available in 1mg, 2mg, and 4mg tablets).

A feature that has attracted clinical attention is pitavastatin's effect on glucose metabolism. Most statins carry a modest risk of new-onset diabetes — a class effect related to their insulin signaling interference. Pitavastatin appears to be neutral or potentially favorable for blood glucose and insulin sensitivity compared to other statins, making it a consideration for patients with prediabetes or borderline glucose control.

Ezetimibe works at a completely different site than statins: it blocks the NPC1L1 transporter in the small intestine brush border, preventing the absorption of dietary cholesterol and bile-derived cholesterol from the gut. Because it acts in the intestine and is only minimally absorbed into the bloodstream, it has a clean side effect profile and very few drug interactions.

Available only in a 10mg tablet (once daily), ezetimibe provides modest standalone LDL reduction of 15–20% — less than any statin. Its real power is additive: when combined with a statin, it lowers LDL by an additional 15–20% beyond what the statin achieves alone. The IMPROVE-IT trial demonstrated that adding ezetimibe to simvastatin after an acute coronary syndrome reduced cardiovascular events, establishing that "lower is better" for LDL even at already low levels.

Ezetimibe is available in fixed-dose combination tablets with simvastatin (Vytorin) and with atorvastatin (Liptruzet), which simplifies the regimen for patients taking both agents.

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a liver protein that binds to LDL receptors on the cell surface and marks them for destruction. Normally, after a receptor pulls LDL from the blood, PCSK9 degrades it before it can be recycled — limiting how many receptors remain available. PCSK9 inhibitors are monoclonal antibodies that block this protein, allowing LDL receptors to persist on the liver surface longer and continue clearing LDL from the bloodstream.

The result is dramatic: PCSK9 inhibitors reduce LDL by 50–65% on top of whatever a patient is already achieving with statins and ezetimibe. In clinical trials (FOURIER for evolocumab, ODYSSEY OUTCOMES for alirocumab), they significantly reduced heart attacks and strokes in patients with established cardiovascular disease.

Both agents are given by subcutaneous injection (auto-injector pen) every 2 to 4 weeks. The primary limitation has historically been cost — PCSK9 inhibitors are far more expensive than statins or ezetimibe, and prior authorization is typically required. They are indicated for familial hypercholesterolemia, statin intolerance with persistently elevated LDL, and high-risk patients whose LDL remains above guideline targets despite maximum oral therapy.

Fibrates are PPAR-alpha agonists — they activate a nuclear receptor that regulates lipid and carbohydrate metabolism. Their primary effect is a substantial reduction in triglycerides (35–50%), with a secondary benefit of raising HDL cholesterol (10–20%). Their LDL-lowering effect is modest and variable, and in patients with very high triglycerides, LDL may actually increase as triglycerides fall.

Fenofibrate (Tricor, Fenoglide, Triglide) and gemfibrozil (Lopid) share the same mechanism but differ crucially in their safety profile when used with statins. Gemfibrozil significantly inhibits the transporters that eliminate statins from the liver, raising statin blood concentrations and substantially increasing myopathy risk. This combination is generally avoided. Fenofibrate does not carry this interaction — it is the preferred fibrate when a fibrate-statin combination is needed.

Available strengths vary by fenofibrate formulation: Tricor (48mg, 145mg), Fenoglide (40mg, 120mg), and Triglide (50mg, 160mg). Gemfibrozil is available as 600mg tablets.

Niacin (vitamin B3 at pharmacologic doses) has a comprehensive effect on the lipid panel: it reduces LDL by 10–20%, reduces triglycerides by 20–40%, and raises HDL by 15–35% — the latter being the largest HDL increase achievable with any available drug. For years, this profile made niacin an attractive add-on therapy.

The clinical picture changed substantially after large randomized trials (AIM-HIGH, HPS2-THRIVE) found that adding niacin to statin therapy did not reduce cardiovascular events despite improving HDL, and actually increased adverse effects — particularly serious muscle toxicity (when combined with laropiprant) and a higher rate of new diabetes diagnoses. This has led most cardiovascular guidelines to de-emphasize niacin as a routine add-on to statins.

Niacin's most notable side effect is flushing — a prostaglandin-mediated dilation of skin blood vessels that causes redness, warmth, and itching, typically of the face and upper body. It is uncomfortable enough that many patients discontinue the medication. Extended-release formulations (Niaspan) and taking an aspirin beforehand can reduce flushing. The prescription ER form Niaspan is available in 500mg, 750mg, and 1000mg tablets.

Bile acid sequestrants are large polymer resins that bind bile acids in the intestine, preventing their reabsorption and forcing the liver to synthesize new bile acids from cholesterol. This depletes the liver's cholesterol pool, upregulates LDL receptors, and draws more LDL from the bloodstream — reducing LDL by 15–25%.

Because these resins are not absorbed into the systemic circulation at all — they remain in the gut and are excreted — they are inherently safe from a systemic toxicity standpoint. This makes them particularly suitable for patients in whom systemic drug exposure is a concern, including pregnant patients who need cholesterol management. They have decades of safety data and were among the first proven treatments for hypercholesterolemia.

The primary limitation is tolerability: cholestyramine (Questran) in particular causes significant GI symptoms — constipation, bloating, and abdominal fullness that patients find difficult to sustain. Colesevelam (Welchol, available as 625mg tablets or 3.75g oral suspension packets) was specifically designed to address this: its chemistry allows for smaller doses and better GI tolerability. Colesevelam also has an FDA indication for improving glycemic control in type 2 diabetes, making it doubly useful in patients managing both conditions.

The critical drug interaction issue is timing: bile acid sequestrants bind to many oral medications in the gut, reducing their absorption. Medications such as warfarin, thyroid hormone, certain antibiotics, and others should be taken at least 1 hour before or 4–6 hours after a bile acid sequestrant.